MK-0616-040

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-0616-040, covering 2025-09-03 to 2025-09-03. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040) [Phase 1]